Understand the source comparison
Testosterone Boost Peptides 2026 Update: Research Comparison
Kisspeptin Analogs GnRH pulse frequency modulation 20–35% increase in intact HPG axis subjects (2025 Mayo Clinic trial) Daily or alternate-day subcutaneous Yes. Late evening or early morning aligned with natural GnRH peaks Most direct pathway for testosterone
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Kisspeptin Analogs
- GnRH pulse frequency modulation
- 20–35% increase in intact HPG axis subjects (2025 Mayo Clinic trial)
- Daily or alternate-day subcutaneous
- Yes. Late evening or early morning aligned with natural GnRH peaks
- Most direct pathway for testosterone elevation in research; requires functional pituitary-gonadal axis; no effect in primary hypogonadism
- Growth Hormone Secretagogues (MK 677, CJC1295 Ipamorelin)
- Indirect via IGF-1 and Leydig cell proliferation
- 12–18% increase in young males with intact HPG axis (Stanford 2025); minimal effect in older subjects
- MK 677: daily oral; CJC1295: once per 5–7 days subcutaneous
- Nocturnal dosing preferred to align with natural GH peaks
- Secondary testosterone effect; primary benefit is GH and IGF-1 elevation; slower onset compared to GnRH-targeting peptides
- Synthetic GnRH Agonists
- LH pulse amplitude increase (initial phase); suppression after continuous use
- 50–80% initial spike in first 7–14 days; then suppression below baseline (receptor desensitization)
- Single-dose or pulsatile administration only
- Critical. Continuous use causes paradoxical suppression
- Research tool only; clinical use limited to fertility protocols; not viable for sustained testosterone elevation
- HCG (Human Chorionic Gonadotropin)
- Direct LH receptor agonist on Leydig cells
- 40–60% increase sustained over weeks (dose-dependent)
- 2–3 times per week subcutaneous
- No circadian requirement
- Gold standard for exogenous LH mimicry; bypasses pituitary; used clinically to maintain testicular function during TRT; not a 'peptide' in the strictest sense but often grouped in protocols
- Marketed 'Testosterone Booster' Peptides (non-specific)
- Varies; often undisclosed or misrepresented
- No validated mechanism or data
- Varies
- Unknown
- Most lack peer-reviewed evidence of HPG axis stimulation; many are growth hormone fragments or collagen peptides mislabeled as testosterone modulators